Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy [clinicaltrials:NCT00003514]
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy [clinicaltrials:NCT00003514]
Bio2RDF identifier
NCT00003514
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00003514
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Antineoplast ...... y or
radiation therapy.
brief title [clinicaltrials_vocabulary:brief-title]
Antineoplaston Therapy in Trea ...... o Surgery or Radiation Therapy
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES:
- ...... ll be accrued for this study.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-11-01T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
keyword [clinicaltrials_vocabulary:keyword]
ACTH-producing pituitary tumor
TSH producing pituitary tumor
growth hormone-producing pituitary tumor
neuroendocrine carcinoma
nonfunctioning pituitary tumor
prolactin-producing pituitary tumor
recurrent Merkel cell carcinoma
recurrent pituitary tumor
somatostatinoma
stage III Merkel cell carcinoma
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2013-07-09T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00003514
official title [clinicaltrials_vocabulary:official-title]
Phase II Study of Antineoplast ...... ncurable Neuroendocrine Tumors
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
secondary id [clinicaltrials_vocabulary:secondary-id]
CDR0000066557
source [clinicaltrials_vocabulary:source]
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2006-12-01T00:00:00Z
identifier
clinicaltrials:NCT00003514
title
Antineoplaston Therapy in Trea ...... o Surgery or Radiation Therapy
@en
type
label
Antineoplaston Therapy in Trea ...... y [clinicaltrials:NCT00003514]
@en